NIKKEI 225
26,804.60 -244.87 (-0.91%) HANG SENG
21,996.89 -422.08 (-1.88%) CRUDE OIL
109.60 -0.18 (-0.16%) GOLD FUTURES
1,819.90 +2.40 (+0.13%) DOW
31,029.31 +82.32 (+0.27%) BTC-GBP
16,570.96 -277.54 (-1.65%)
EVOTEC SE (EVT.BE)
| Previous close | 24.27 |
| Open | 24.32 |
| Bid | 23.38 x 145200 |
| Ask | 24.05 x 140700 |
| Day's range | 23.37 - 24.32 |
| 52-week range | 20.39 - 45.70 |
| Volume | |
| Avg. volume | 119 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Evotec SE reports results of Annual General Meeting 2022
DGAP-News: Evotec SE / Key word(s): AGM/EGMEvotec SE reports results of Annual General Meeting 2022 22.06.2022 / 16:20 The issuer is solely responsible for the content of this announcement. ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY CAMILLA MACAPILI LANGUILLE ELECTED AS NEW MEMBER OF THE SUPERVISORY BOARD; KASIM KUTAY RESIGNS FROM SUPERVISORY BOARD AUTHORISED CAPITAL 2022 RESOLVED REVISED REMUNERATION SYSTEM FOR MANAGEMENT BOARD APPROVEDHamburg, Germany, 22 June 2022:Evotec SE (Frankfur
- Zacks
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.
- EQS Group
Evotec enters a drug discovery collaboration with Janssen
DGAP-News: Evotec SE / Key word(s): MiscellaneousEvotec enters a drug discovery collaboration with Janssen 14.06.2022 / 07:30 The issuer is solely responsible for the content of this announcement. STRATEGIC PARTNERSHIP LEVERAGES EVOTEC’S PROPRIETARY PLATFORM CAPABILITIES IN THE FIELD OF PROTEIN HOMEOSTASISHamburg, Germany, 14 June 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a drug discovery collaboratio
